Could Semaglutide Expand Treatment Options for Children With Obesity?

A newly announced clinical trial may mark an important step toward expanding medical treatment for childhood obesity. On September 7, 2026, Novo Nordisk reported topline results from STEP Young, a phase 3 trial of once-weekly semaglutide in children ages 6 to younger than 12 with obesity.

After 68 weeks, 40.4% of children assigned to semaglutide were below the obesity threshold, compared with none of those assigned to placebo. Both groups also received support for a reduced-calorie diet and increased physical activity.

The result is notable because medication options for younger children remain limited. It also arrives amid a broader change in how clinicians approach pediatric obesity: as a complex chronic disease that may require more than advice about diet and exercise alone.

Still, the announcement is an early look at the study. Families and clinicians will need the complete data before they can fully judge the treatment’s benefits and risks.

What the STEP Young trial found

STEP Young enrolled 165 children in a randomized, double-blind, placebo-controlled multinational trial. More than 85% had class II or class III severe obesity at enrollment. Children received either semaglutide at a maximum weekly dose of 1.7 or 2.4 milligrams, based on starting weight, or a placebo. The primary endpoint was the percentage change in BMI from baseline through week 68.

Novo Nordisk said the study met that primary endpoint, meaning BMI declined more with semaglutide than with placebo. The company highlighted a secondary result that may be easier for families to understand: Roughly two in five children receiving semaglutide moved from the obesity range into the overweight or normal-weight range on age- and sex-specific growth charts.

Ania M. Jastreboff, M.D., Ph.D., Yale Obesity Research Center, said:

Treatment with semaglutide resulted in a BMI percentile category below the obesity threshold in approximately 40% of the children.

For children, BMI is interpreted differently than it is for adults. Clinicians use percentiles that account for age and sex because children are still growing. Crossing below the obesity threshold therefore reflects a change in BMI category, not a single adult-style BMI cutoff.

Why these findings matter

Childhood obesity can affect health well before adulthood. It is associated with cardiometabolic risk factors as well as depression, disordered eating, bullying, and reduced quality of life. Severe obesity is also likely to persist into adulthood, increasing the likelihood that related complications will appear earlier.

Let’s note that Wegovy, the semaglutide product used for chronic weight management, is already used in older populations, but current reporting notes that GLP-1 weight-loss drugs are not approved for children younger than 12. STEP Young could therefore support a future regulatory review for a group with fewer evidence-based medication choices.

Medication would not replace comprehensive care

The trial did not test semaglutide by itself. Every participant received lifestyle support, including dietary changes and increased physical activity. That detail matters: Pediatric obesity treatment is typically family-centered and may involve nutrition, physical activity, sleep, behavioral health, and management of related medical conditions. If semaglutide is eventually authorized for younger children, it would be considered one possible component of individualized care rather than a standalone solution.

Important questions remain

The 40.4% figure is promising, but the initial announcement did not disclose several details needed for a complete benefit-risk assessment. Contemporary Pediatrics noted that the topline release did not provide the mean BMI change, the difference between groups, confidence intervals, or a full statistical analysis. It also did not report detailed rates of gastrointestinal side effects, serious adverse events, or treatment discontinuation.

Novo Nordisk reported that overall safety and tolerability were consistent with prior semaglutide and liraglutide studies and that no new concerns involving growth or pubertal development were identified. Even so, longer follow-up is essential in children. Researchers and clinicians will want to understand effects on growth, puberty, body composition, metabolic health, emotional well-being, and what happens if treatment stops.

STEP Young offers encouraging evidence that semaglutide, combined with lifestyle treatment, may help some children with severe obesity achieve a clinically meaningful change in BMI category. It does not yet establish that the medication should be broadly used in children under 12.

Full results are expected to be presented at ObesityWeek in November 2026, when independent experts will be able to examine the magnitude of BMI reduction, adverse events, discontinuations, and other outcomes in greater detail. In the meantime, parents should not use medication prescribed to another person or seek a GLP-1 product without age-appropriate medical evaluation and monitoring.

Your responses and feedback are welcome!

Source: “Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification,” GlobeNewswire, 9/7/26
Source: “Semaglutide improves BMI category in children aged 6 to 11 years in phase 3 trial,” Contemporary Pediatrics, 9/8/26
Source: “GLP1 Drugs Work for Kids, Says Novo Nordisk. They Could Be Another Huge Market.,” Barrons.com, 9/8/26
Image by Vitaly Gariev/Pexels

Semaglutide Trials Show Promising Results

GLP-1 medications have transformed obesity treatment for many adults and adolescents. Now, new research suggests these drugs may also benefit younger children with obesity — even as their rapidly increasing use raises important questions about safety, access, and long-term care.

Results from Novo Nordisk’s late-stage STEP Young trial found that 40.4% of children ages 6 to younger than 12 who received semaglutide were no longer classified as having obesity after 68 weeks, assuming they fully followed the prescribed treatment.

Semaglutide is the active ingredient in Wegovy, a once-weekly injectable medication used for chronic weight management. Wegovy is currently approved in the United States for adults and adolescents ages 12 and older with obesity, but not for children younger than 12.

The STEP Young trial compared once-weekly semaglutide injections with a placebo. Every participant also received lifestyle support throughout the study, including guidance on a reduced-calorie diet and increased physical activity.

According to Novo Nordisk, the trial met its primary goal by demonstrating a greater reduction in body mass index, or BMI, after 68 weeks among children receiving semaglutide compared with those receiving a placebo.

Martin Holst Lange, Novo Nordisk’s chief scientific officer, said:

We are encouraged by the positive STEP Young results and semaglutide’s potential to help children living with obesity who need medical treatment, alongside lifestyle changes, to better manage their obesity.

The company also reported that semaglutide’s overall safety and tolerability were consistent with findings from clinical trials involving adolescents and adults. However, additional study details and longer-term monitoring will be important for understanding how treatment may affect children as they grow and develop.

The trial results arrive as GLP-1 use among children younger than 12 is already increasing in the United States. A separate study led by researchers at NYU Langone Health found that GLP-1 prescribing among children ages 8 to 11 with obesity and without diabetes was 310 times higher in June 2026 than when prescribing began in 2019. More than 20,000 children in this age group received GLP-1 prescriptions during the study period. The study results were published in Pediatrics earlier this month.

Despite that rapid growth, the overall percentage of young children receiving these medications remains low. Prescriptions are still less common among children ages 8 to 11 than among adolescents ages 12 to 17.

Lead investigator Babak J. Orandi, M.D., Ph.D., said:

Our study offers the first national overview in young children of the use of GLP-1 drugs to fight the obesity epidemic in the United States and shows that while the absolute numbers of children under the age of 12 receiving GLP-1 treatment is still low, GLP-1 use is accelerating rapidly.

Researchers examined electronic health records from Epic Cosmos, a national database containing information from more than 300 million patients across thousands of hospitals and health clinics.

Nearly 94% of the young children prescribed GLP-1 medications had severe obesity. Approximately 65% also had at least one obesity-related health condition, such as high blood pressure, elevated cholesterol, or sleep apnea. About one-quarter had prediabetes.

These findings suggest that physicians have generally been prescribing the medications to children facing significant health risks rather than using them as a routine weight-loss intervention.

GLP-1 medications can support weight loss by reducing appetite, slowing digestion and improving blood sugar regulation. For children with severe obesity, treatment may also help reduce the likelihood of developing diabetes, liver disease, cardiovascular problems and other chronic conditions later in life.

Dr. Orandi described careful GLP-1 use as “a valuable tool in confronting the obesity epidemic among young Americans.” He also emphasized the need to monitor treated children over time to ensure the medications remain safe and effective.

The NYU Langone study also identified a potential socioeconomic divide. Young children with obesity living in higher-income communities were 55% more likely to receive GLP-1 medications than children living elsewhere.

The medications can be costly, and insurance coverage varies considerably. Families with stronger insurance benefits, greater financial resources or easier access to pediatric specialists may therefore be better positioned to obtain treatment.

Co-senior author Allan B. Massie, Ph.D., said,

Physicians and health policymakers alike have a responsibility to ensure, as use of GLP-1 medications continues to rise, that all young children with obesity who need these drugs have access to them.

Addressing this disparity will become increasingly important if clinical trials support expanding GLP-1 approvals to younger age groups.

The STEP Young results are promising, but they do not mean semaglutide is appropriate for every child with obesity. Treatment decisions should consider the child’s overall health, obesity severity, related medical conditions, developmental needs, and family circumstances.

Medication is also not presented as a replacement for nutrition, physical activity, or ongoing medical care. In the STEP Young trial, semaglutide was used alongside structured lifestyle changes.

Further research will be needed to answer several key questions, including how long children may need treatment, whether weight returns after medication is discontinued, and how extended use could affect growth, development, and long-term health.

For now, the two studies point to a rapidly evolving area of pediatric medicine. GLP-1 medications may eventually offer an important option for younger children with severe obesity, but their growing use will require careful prescribing, long-term monitoring, and equitable access to qualified medical care.

Your responses and feedback are welcome!

Source: “Novo Nordisk says semaglutide cut obesity rates in young children in trial,” Reuters, 9/7/26
Source: “Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification,” GlobeNewswire, 9/7/26
Source: “GLP-1 Use Among Young Children With Obesity in US Remains Rare but Is Rising Rapidly,” NYU Langone Health, 9/4/26
Image by Vanessa Loring/Pexels

Are Pediatric GLP-1 Prescriptions Moving Faster Than the Evidence?

The rapid rise of glucagon-like peptide-1 (GLP-1) receptor agonists has transformed the treatment of obesity. Medications such as semaglutide (Wegovy), tirzepatide (Zepbound and Mounjaro), and liraglutide (Saxenda) have demonstrated an ability to produce significant weight loss in adults, making them some of the most consequential pharmaceutical developments in obesity medicine in decades. Increasingly, however, these medications are being prescribed to children and adolescents.

That expansion raises important questions. How strong is the long-term safety evidence in developing children? What are the potential consequences of altering appetite, digestion, body composition, and other physiological systems during childhood? And are medications being used to manage childhood obesity without adequately addressing the environmental and lifestyle factors contributing to it?

These questions deserve careful consideration as GLP-1 medications become a larger part of pediatric medicine.

In January 2023, the American Academy of Pediatrics published its Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. The recommendations represented a significant shift toward more intensive treatment of childhood obesity. The guideline supported consideration of pharmacotherapy in pediatric patients, including off-label treatment in some younger children, while also recommending evaluation for bariatric surgery for certain adolescents beginning at age 13.

Its release also came shortly after the FDA expanded approval of GLP-1 therapy for adolescents. Questions about potential conflicts of interest subsequently emerged.

According to a July 2025 BMJ investigation, GLP-1 drug manufacturers provided approximately $2 million in corporate sponsorship to the AAP between 2012 and 2024. Investigators also identified pharmaceutical-industry payments to 10 of the 27 members of the guideline-writing committee and 17 of 77 members of the organization’s national leadership.

Those financial relationships were reportedly not disclosed within the guideline or its accompanying technical report. Financial relationships do not by themselves demonstrate that a clinical recommendation is incorrect. They do, however, make transparency particularly important when recommendations could substantially increase medication use among children.

Since the release of the guidelines, prescribing has increased substantially. The figures include:

• A 38% increase in pediatric GLP-1 prescriptions during the first year following the guideline.
• A reported 700% increase for two particular GLP-1 medications.
• CDC data showing approximately a 300% increase in adolescent obesity-medication prescribing between 2020 and 2023.
• Semaglutide accounting for approximately 57% of adolescent obesity prescriptions, with the majority going to adolescents with severe obesity.

Although only a small percentage of adolescents with obesity currently receive these medications, the speed at which prescribing is increasing makes the quality and duration of pediatric safety evidence increasingly important.

GLP-1 receptors are not confined to the digestive system. They are found throughout the body, including in the cardiovascular system. Clinical trials have documented small increases in heart rate among patients taking GLP-1 receptor agonists.

There is also a more indirect cardiovascular concern. Nausea, vomiting, and diarrhea — well-recognized side effects of GLP-1 drugs — can cause dehydration and significant electrolyte abnormalities. This may be especially relevant in younger patients because pediatric prescribing information for Mounjaro reports a higher incidence of vomiting and abdominal pain among children than adults.

One of the less frequently discussed issues surrounding GLP-1 medications is body composition. When a patient loses weight, not all of the lost weight comes from body fat. This issue may carry different implications for children than for adults.

Childhood and adolescence are critical periods for building muscle and achieving peak bone mass. Researchers therefore need to understand whether prolonged pharmacologically-induced weight loss could affect skeletal development, muscle development, or long-term body composition.

There is also the issue of what happens when treatment ends. Loss of metabolically active lean tissue may be one of several factors contributing to weight regain after discontinuation, potentially making GLP-1 therapy a long-term treatment rather than a temporary intervention.

Perhaps the largest unanswered question involves the widespread distribution of GLP-1 receptors themselves. They are found in the brain, gastrointestinal tract, pancreas, heart, kidneys, lungs, thyroid, blood vessels, adipose tissue, immune cells, and bone. Researchers continue to investigate exactly what those receptors do in each organ system and how prolonged pharmacological activation may affect them.

Interest in GLP-1 medications as potential treatments for conditions such as neurodegenerative disease further demonstrates that their biological effects extend well beyond blood-sugar control and appetite regulation. That does not mean these additional effects are necessarily harmful. It means that the biological picture is more complex than appetite suppression alone — and that long-term pediatric research is especially important.

The duration and size of existing pediatric trials remain significant limitations. The pediatric approval of Mounjaro for type 2 diabetes relied on a 30-week study involving 99 pediatric participants. The longest pediatric weight-loss study referenced lasted 68 weeks. Neither timeframe can establish what may happen over many years of treatment with respect to growth, puberty, bone density, neurodevelopment, reproductive development, or other long-term outcomes.

The debate surrounding pediatric GLP-1 prescribing ultimately involves a larger question: What is driving childhood obesity in the first place?

Childhood obesity develops within a complicated environment involving food quality and availability, highly processed diets, refined carbohydrates, sedentary behavior, screen time, sleep, socioeconomic conditions, genetics, family habits, environmental exposures, and numerous other influences.

GLP-1 drugs may help reduce appetite and body weight, but they do not directly change that broader environment. That distinction matters.

For some children and adolescents with severe obesity or related metabolic disease, pharmacotherapy may ultimately prove to have an appropriate place alongside nutrition, physical activity, behavioral care, family support, and treatment of related medical conditions. But medication should not prevent clinicians, families, researchers, or policymakers from confronting the circumstances contributing to the rise in childhood obesity.

The central concern surrounding pediatric GLP-1 prescribing is not whether these medications can produce weight loss. The available evidence shows that they can. The larger question is whether enough is known about what prolonged treatment does to a developing body.

Children are not simply smaller adults. Their bones are developing. Their muscles are growing. Their endocrine systems are changing. Their brains and reproductive systems are maturing.

Let’s close with the words of the pediatrician and the author of the article we’ve used as one of the sources for this post, Dr. Michelle Perro:

Underlying this is a more fundamental question. Childhood obesity is a symptom of an altered food environment: ultra-processed foods, GMOs and their associated pesticides, refined carbohydrates, seed oils, endocrine-disrupting chemicals, and a sedentary, screen-based childhood. Pharmacologic appetite suppression addresses none of these. It intervenes downstream of the pathology while leaving the causes intact.

A therapeutic approach that treats the symptom while ignoring the etiology and that commits a child to indefinite medication without long-term safety data does not meet the standard of care to which pediatric patients are entitled.

Your responses and feedback are welcome!

Source: “GLP-1 Receptor Agonists in Pediatric Patients: An Evidence Review and Cautionary Analysis,” GMOScience.org, 8/27/26
Source: “Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity,” Pediatrics, 1/3/23
Image by Gustavo Fring/Pexels

Is Obesity Reversible?

Obesity may affect the body differently at age 15 than it does at age 45. New research from Duke University School of Medicine suggests that adolescents retain a level of metabolic flexibility that is largely diminished by adulthood.

The study, published in the Journal of Clinical Investigation, found that although teenagers with obesity show early biological signs associated with metabolic disease, their bodies may still be able to adapt to the strain of excess weight. This resilience could make adolescence an especially important time for treatment.

By demonstrating that the biology of obesity changes with age, the findings point to a potential window in which obesity-related metabolic damage may be slowed, prevented, or possibly reversed before it becomes deeply established. John Rawls, Ph.D., a professor of molecular genetics and microbiology and member of the Duke Microbiome Center, said:

For a long time, medicine has tended to treat adolescents as little adults… But teenagers are still growing, building muscle and bone, and using energy in ways that are very different from adults. We wanted to understand how those differences shape obesity.

Why this research matters

Nearly one in five children in the United States has obesity. Without effective intervention, most children with obesity will continue to have obesity as adults, according to study co-author Sarah Armstrong, M.D., a pediatrician and medical weight management specialist at Duke Health.

The transition from adolescence to adulthood does not occur at exactly the same time for everyone. It generally takes place during the late teenage years and early 20s for women and during the early to mid-20s for men.

Researchers are now looking more closely at when the long-term health effects of obesity become biologically embedded. Understanding that timeline could help healthcare providers identify when treatment is most likely to alter a young person’s future health.

Teenagers’ gut microbiomes behave differently

The Duke research team examined two biological systems frequently connected to obesity: the microbiome and the metabolome. The gut microbiome is the community of bacteria and other microorganisms living within the digestive tract. The metabolome includes the chemicals produced as the body and its microbes break down food, generate energy, and carry out other essential processes.

Researchers first analyzed gut microbes collected from 287 teenagers participating in the Pediatric Obesity Microbiome and Metabolism Study. They confirmed that the microbiomes of adolescents with obesity differed in composition from those of teenagers at a healthy weight.

Jessica McCann, Ph.D., a senior research associate in molecular genetics and microbiology, then transplanted microbiome samples from adolescents with and without obesity into germ-free mice. In adult obesity research, transferring gut microbes associated with obesity can sometimes cause recipient mice to gain additional weight. That did not happen when the Duke researchers used microbiota collected from teenagers with obesity.

The result suggests that obesity-related changes in the microbiome are already beginning during adolescence, but those microbes may not yet be contributing to disease in the same way they often do in adults. Dr. McCann said:

This suggests there’s a developmental window in which the microbiome becomes involved in obesity… The relationship between the host and the microbiome may still be developing during adolescence, which means there may be an opportunity to change its trajectory.

In other words, the adolescent microbiome may be changing, but its relationship with the rest of the body has not necessarily become fixed. That could leave room for treatments that influence the microbiome before harmful patterns become more firmly established.

Early warning signs

Working with the Duke Molecular Physiology Institute, the research team also investigated how adolescents process nutrients. Adults with obesity frequently have elevated levels of branched-chain amino acids. They may also have higher levels of related substances called branched-chain keto acids, or BCKAs. Elevated BCKAs have been linked to insulin resistance and type 2 diabetes.

The adolescents in the Duke study displayed a different metabolic pattern. Their branched-chain amino acid levels were elevated, but their BCKA levels remained comparatively low.

The elevated amino acids may represent an early warning sign. However, the relatively low BCKA levels suggest that the teenagers’ bodies were still adapting to the metabolic pressure associated with excess weight. According to Dr. McCann,

The metabolome is showing early signs of disease progression, but it’s also showing evidence of adaptive plasticity.

This adaptive plasticity may help explain why obesity during adolescence is not biologically identical to obesity in adulthood. Teenagers’ bodies are still developing and may remain more capable of adjusting how they use and process nutrients.

A critical opportunity for obesity treatment

The findings strengthen the case for addressing obesity early rather than waiting until adulthood or until related conditions, such as insulin resistance, have fully developed. “The evidence increasingly supports intervening as early as possible,” said Dr. Armstrong, a professor of pediatrics at Duke.

During this period of metabolic flexibility, adolescents may be more responsive to weight-management strategies involving nutrition, physical activity, medication, or future microbiome-based therapies. The research does not suggest that one treatment will work for every teenager. Instead, it highlights the possibility that timing and individual biology may influence which approaches are most effective.

The study also challenges the idea that adolescent obesity should simply be managed using adult treatment models. Early biological warning signs do not necessarily mean that long-term metabolic disease is inevitable. By recognizing adolescence as a unique developmental stage, healthcare providers may have an important opportunity to intervene before temporary metabolic strain becomes a lasting health burden.

Your responses and feedback are welcome!

Source: “Study finds that obesity in adolescence may be more reversible than previously thought,” MedicalXPress, 8/24/26
Source: “Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy,” JCI, 7/15/26
Image by CDC/Pexels

Opposite Signals Both Promote Weight Loss

Scientists have solved a puzzling question about a brain receptor involved in appetite: How can activating it and blocking it both lead to weight loss? The answer appears to depend on location.

In a study involving mice, researchers at the University of Cambridge found that drugs targeting the glucose-dependent insulinotropic polypeptide receptor, or GIPR, can influence body weight through separate regions of the brain. Activating the receptor in the brainstem reduced appetite, while blocking it in the hypothalamus strengthened the brain’s response to signals of fullness.

The findings, published in Nature Metabolism, could help explain why obesity medicines with seemingly contradictory mechanisms can produce similar outcomes. They may also point toward more effective combinations of GIPR-targeting treatments and drugs that act on the GLP-1 receptor, the target of medicines such as Wegovy and Ozempic.

As we know, substantial and sustained weight loss is often difficult to achieve through changes in diet and physical activity alone. Newer obesity medications work partly by influencing the biological systems that control hunger, fullness, and blood sugar.

Wegovy and Ozempic, for example, activate the glucagon-like peptide 1 receptor, commonly known as GLP-1R. Other treatments act on GLP-1R and GIPR at the same time.

That is where the scientific puzzle begins. Mounjaro and Zepbound activate GIPR as part of their mechanism. MariTide, an investigational medicine in phase 3 clinical trials, takes the opposite approach by blocking GIPR while activating GLP-1R. Both strategies can support weight loss, even though one turns the GIP receptor on and the other prevents it from working.

The Cambridge research suggests these approaches are not producing the same effect in the same place. Instead, they appear to engage distinct brain circuits that ultimately lead to reduced food intake and body weight.

To investigate, the researchers used genetically engineered mice in which GIPR had been removed from selected parts of the brain. Some mice lacked the receptor in the brainstem, an area near the spinal cord that helps regulate appetite and nausea. Others lacked it in the hypothalamus, which plays a central role in hunger, energy balance, and body-weight regulation. A third group of mice had not been genetically modified and served as a control.

The animals received different combinations of three types of treatment: a GIPR agonist that activated the receptor, a GIPR antagonist that blocked it, and a GLP-1-based drug. The researchers then measured how much the mice ate, how their body weight and fat mass changed, how well they regulated blood sugar, and which parts of their brains became active.

By comparing the results among the three groups, the scientists were able to identify the brain regions required for each treatment to work.

The experiments indicated that GIPR agonists depend largely on the brainstem. When the receptor was activated in this area, the mice ate less and lost weight. But when GIPR had been removed from the brainstem, the appetite-reducing effect was weakened, suggesting that this region is a key site of action for drugs that stimulate the receptor.

This helps explain how medicines that activate both GIPR and GLP-1R can influence eating behavior. Their effects are not limited to the digestive system or the pancreas; they also involve neural circuits that help determine when an animal stops eating.

GIPR antagonists worked differently. Their weight-loss effects depended more heavily on the hypothalamus. In this part of the brain, GIPR appears to act like a “brake,” reducing the strength of fullness signals coming from the brainstem.

Blocking the receptor releases that brake. As a result, signals telling the brain that the body has had enough food may become more powerful.

This means that activating and blocking GIPR can each reduce eating, but they reach that outcome through different routes. Activation directly engages appetite-suppressing pathways in the brainstem, while antagonism appears to make the hypothalamus more receptive to signals of satiety. That distinction may also explain why both strategies can complement GLP-1 medicines.

The findings offer a clearer biological explanation for the design of MariTide, which combines GIPR antagonism with GLP-1R activation. Because the two components may act through separate but interacting circuits, combining them could potentially produce a greater effect than targeting either pathway alone.

The researchers also found signs that GIPR antagonism could strengthen the effects of medicines aimed at the amylin receptor, another emerging target for obesity treatment. If that finding translates beyond mice, blocking GIPR might eventually be used to enhance several different types of weight-loss drugs — not only GLP-1 therapies.

Dr. Jo Lewis, the study’s first author from the Institute of Metabolic Science at the University of Cambridge, said:

Understanding which brain circuits respond to these medications — and how they do so — could help us design better drugs that produce more weight loss with fewer side effects, and which might work in combination with other obesity medicines to even greater effect…

Our work also strengthens the idea that the brain is central to obesity treatment. Obesity drugs are not acting simply on the gut or pancreas. Instead, they have important effects on specific, identifiable brain circuits that regulate appetite and food intake.

The research provides a useful framework for understanding an apparent contradiction in obesity pharmacology. Drugs that activate GIPR and drugs that block it are not necessarily cancelling out the same biological process. They may be acting in different brain regions, on different circuits and at different stages of the body’s appetite response.

However, the work was conducted in mice. Further research will be needed to determine how closely the same mechanisms apply to humans and whether targeting these pathways in combination can reliably improve weight loss, blood sugar control, or tolerability in patients.

Even so, the results underline an important shift in the science of obesity treatment. The effects of these medicines cannot be understood solely by studying the gut, insulin production, or digestion. Their success may depend just as much on where — and how — they alter communication within the brain.

Your responses and feedback are welcome!

Source: “Scientists solve the mystery of a brain “switch” that can trigger weight loss in opposite ways,” ScienceDirect, 8/15/26
Source: “Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism,” Nature Metabolism, 7/24/26
Image by MART PRODUCTION/Pexels

Yale Study: Hunger Neurons in Weight Loss

For years, scientists believed that a group of brain cells known as agouti-related peptide, or AgRP, neurons played a straightforward role in metabolism: They stimulated hunger and resisted weight loss.

New research from Yale suggests the story is far more complicated.

In a study published in the Proceedings of the National Academy of Sciences (PNAS), researchers found that semaglutide, the active ingredient in Ozempic and other GLP-1 medications, appears to activate AgRP neurons rather than suppress them. Even more surprisingly, the study indicates that these hunger-promoting neurons may be necessary for maintaining the fat loss produced by the medication.

The findings challenge a long-standing assumption about the brain’s hunger circuitry and may help explain why newer GLP-1 therapies generate more substantial and lasting results than earlier weight-loss drugs.

Mateus d’Ávila, a Ph.D. candidate in neuroscience working in Tamas Horvath’s lab in the Department of Comparative Medicine at Yale School of Medicine (YSM) and first author of the study, said:

This completely changes how we think about the mechanism involved in these medications and provides new insight into the biology underlying their long-term effects, opening an avenue for the development of more efficient drugs.

The arrival of Ozempic and related GLP-1 therapies changed expectations, with some patients achieving sustained reductions of 10% to 15% of their body weight or more. Scientists know that these medications can reduce appetite and food intake. But appetite suppression alone may not fully account for their effectiveness.

Previous generations of weight-loss drugs could also substantially reduce hunger, yet they did not consistently produce the same degree of lasting weight loss as seen with semaglutide. That difference led the Yale team to suspect that GLP-1 medications were affecting additional biological systems.

One prominent theory held that the drugs worked partly by reducing the activity of AgRP neurons. Located in the brain’s hypothalamus, these neurons are strongly associated with hunger and feeding behavior. Because they encourage animals to seek and consume food, it seemed reasonable to assume that successful weight-loss treatments would need to inhibit them.

However, the role of AgRP neurons during long-term GLP-1 treatment had not been directly tested in a living organism. The Yale researchers set out to fill that gap.

Using a mouse model, the team combined several experimental approaches to examine what happened during semaglutide treatment. They tracked changes in body weight, food consumption, metabolism and energy expenditure.

The researchers also used genetic techniques to selectively remove or silence AgRP neurons. This allowed them to test whether the neurons merely responded to semaglutide or were actually required for the medication’s sustained effects.

The study results are striking. In mice genetically modified to lack AgRP neurons, GLP-1 treatment could initiate weight loss but could not sustain it. That suggested the neurons traditionally viewed as opponents of weight reduction were, in fact, helping preserve the drug’s long-term benefits.

Further investigations using electron microscopy, molecular biology and electrophysiology produced another unexpected finding: Semaglutide activated the AgRP neurons instead of inhibiting them. The researchers propose that this activation reflects the brain’s adaptation to the calorie deficit produced by GLP-1 treatment.

When calorie intake declines, AgRP neurons become more active as part of the body’s normal response to an energy shortage. Their best-known function is to increase hunger. The new study, however, suggests that their role is not limited to driving food intake. Under semaglutide treatment, the neurons may also participate in coordinating the loss of body fat.

In other words, the same neural system that signals a need for food may also help the body manage its energy stores during prolonged weight loss. This does not mean that hunger itself causes weight loss. Rather, it points to a previously unrecognized interaction between semaglutide, the brain’s response to calorie restriction, and the biological processes that determine whether lost weight stays off.

The discovery adds an important layer of complexity to scientists’ understanding of GLP-1 medications. Instead of simply shutting down the brain’s hunger signals, semaglutide may recruit parts of the hunger system and redirect their activity in ways that support sustained changes in body fat.

Because the study was conducted in mice, the results cannot yet be assumed to apply directly to humans. Researchers will need to determine whether the same neural mechanism operates in people taking semaglutide and other GLP-1 medications.

Still, identifying how the brain adapts during treatment could influence the next generation of obesity therapies. A more complete understanding of AgRP neurons might help scientists develop medications that preserve the benefits of GLP-1 drugs while improving their effectiveness, reducing unwanted effects, or helping a broader group of patients maintain weight loss.

d’Ávila said,

By identifying a previously unrecognized neural mechanism involved in sustaining weight loss, our work provides new biological insights that could eventually help researchers design therapies that are even more effective or have fewer side effects.

Your responses and feedback are welcome!

Source: “New study may change how we think about GLP-1s,” Yale News, 8/10/26
Source: “AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice,” PNAS, 8/4/26
Image by denis1203.

Are GLP-1 Medications Replacing Bariatric Surgery?

The treatment landscape for obesity is changing rapidly, particularly among adolescents and young adults. New research suggests that GLP-1 medications have quickly become the most common medical treatment for younger people with obesity, while the use of metabolic and bariatric surgery has declined substantially.

A study published in JAMA Pediatrics found that the number of adolescents and young adults receiving GLP-1 medications increased sharply between 2022 and 2025-2026. During the same period, the proportion undergoing metabolic and bariatric surgery dropped significantly.

The findings offer a glimpse into how quickly obesity treatment has evolved as medications such as semaglutide have become more widely available. They also raise important questions about equitable access to treatment.

Researchers from the study examined real-world treatment patterns among more than 204,000 adolescents and young adults between the ages of 12 and 29 who received obesity treatment. The team compared treatment during two periods: May through November 2022, before semaglutide became widely available for adolescents with obesity, and June 2025 through January 2026, when GLP-1 medications were much more established in obesity care.

Researchers looked at whether patients received GLP-1 medications, metabolic and bariatric surgery, or both. They also examined differences related to age, sex, race and ethnicity, insurance status, and neighborhood socioeconomic conditions.

The results showed a striking change in how younger patients were treated. In 2022, 88.2% of patients receiving obesity treatment were treated exclusively with GLP-1 medications. By 2025-2026, that figure had risen to 96.1%. At the same time, the proportion of patients receiving metabolic and bariatric surgery declined from 11.6% to 3.7%.

Combination treatment remained uncommon. Only about 0.2% of patients received both GLP-1 medications and bariatric surgery during the study periods.

According to lead researcher Sarah Messiah, Ph.D., M.P.H., the study represents a major turning point in pediatric and young-adult obesity treatment. She said:

Our team’s study captures an inflection point in pediatric obesity treatment… While only a small proportion of adolescents and young adults currently receive both therapies, combination treatment was virtually nonexistent before GLP-1 medications became widely available. We’re now seeing clinicians integrate these therapies in different ways as obesity care continues to evolve.

Does this mean bariatric surgery is going away? Not necessarily.

The study does not establish that GLP-1 medications are superior to bariatric surgery, nor does it suggest that surgery is no longer an important treatment option. Instead, the findings demonstrate how the availability of highly effective medications has changed clinical practice.

Metabolic and bariatric surgery remains an established treatment option for some adolescents and young adults with severe obesity, particularly when other approaches have not produced sufficient results. GLP-1 medications offer another option that can be used without surgery, potentially changing how doctors and families approach treatment decisions.

For some patients, medication may be preferred because it avoids an operation. Others may benefit from surgical treatment based on their individual health needs, severity of obesity, response to previous treatments, and other medical considerations.

While the rapid growth of GLP-1 use is significant, the study also revealed disparities in who receives these medications. Older patients, patients with commercial insurance, and people living in higher-income neighborhoods were more likely to receive GLP-1 treatment.

Those differences suggest that simply having effective obesity medications available does not mean every patient has equal access to them. Insurance coverage, medication costs, healthcare availability, and socioeconomic circumstances can all influence whether a patient is able to receive treatment.

This is particularly important as obesity medications become a more prominent part of care for adolescents and young adults. If access remains concentrated among people with greater financial resources or more comprehensive insurance, existing health disparities could persist or widen.

For families navigating childhood or young-adult obesity, the research highlights how quickly treatment options are changing. Just a few years ago, bariatric surgery was one of the major medical interventions available for young people with severe obesity who needed more intensive treatment. Today, GLP-1 medications are increasingly becoming part of the conversation.

Your responses and feedback are welcome!

Source: “GLP-1 drugs are changing how teens and young adults treat obesity,” Consumer Affairs, 8/4/26
Source: “GLP-1 use rising rapidly among U.S. adolescents, young adults,” UT Southwestern Medical Center, 7/20/26
Image by Pavel Danilyuk/Pexels

How Young Is Too Young for GLP-1 Meds?

GLP-1 medications such as Wegovy and Zepbound have reshaped obesity treatment for adults and are increasingly being used to help adolescents with obesity. Now, a more challenging question is taking center stage: Should these medications be used in even younger children?

While the U.S. Food and Drug Administration (FDA) has approved some GLP-1 medications for adolescents ages 12 and older who meet specific criteria, a small but growing number of physicians are prescribing them off-label for elementary school-age children with severe obesity. The trend has sparked debate among healthcare providers, researchers, and parents over whether early intervention outweighs the unknown long-term risks.

Not all GLP-1 medications are approved for pediatric obesity treatment, and those that are have age restrictions. Wegovy, for example, is approved for chronic weight management in adolescents aged 12 and older who have obesity and meet certain medical requirements.

Doctors generally reserve these medications for children whose obesity has not improved despite comprehensive lifestyle interventions, including healthier eating habits, increased physical activity, and behavioral support.

The medications are not intended for children who simply want to lose weight. Instead, they are considered for young people with obesity who face increased risks for serious health conditions such as type 2 diabetes, high blood pressure, fatty liver disease, and cardiovascular disease.

Many obesity specialists argue that treating obesity early may prevent lifelong health complications. Clinical trials have shown that GLP-1 medications can produce significant weight loss in adolescents when combined with lifestyle changes. Physicians who support their use view obesity as a chronic disease that often requires medical treatment alongside healthy habits.

For some children with severe obesity, waiting until adulthood may allow health problems to progress. Dr. Jessica Reilly, medical director of the Strong4Life pediatric obesity clinic at Children’s Healthcare of Atlanta, sees the consequences firsthand:

I see kids who have developed Type 2 diabetes at 10, 11 years old… They need help so desperately.

Although GLP-1 medications are approved for obesity beginning at age 12, some physicians are prescribing them off-label for children as young as six. One widely reported example involves nine-year-old twins Ayden and Kayden Gatlin-Wright. After years of unsuccessful efforts with diet, exercise, and nutritional counseling, doctors discovered the brothers carried a genetic mutation that affects feelings of fullness and increases their risk of obesity.

Despite working closely with healthcare professionals, their body mass index (BMI) continued to rise, and by age seven, they showed elevated blood sugar levels, abnormal cholesterol, and signs of liver dysfunction.

Their parents decided to pursue off-label treatment with Wegovy, paying approximately $700 every four weeks out of pocket for both children.

The medication appears to be helping. According to reports, Ayden’s BMI has declined by about 5%, while Kayden’s has fallen by roughly 7%. Beyond the numbers, their parents say the boys are developing healthier habits and enjoying more energy.

Despite encouraging early results, many pediatric experts urge caution. One of the biggest concerns is the lack of long-term research on children who might remain on these medications for many years — or even decades.

Questions remain about:

• How long children may need to stay on GLP-1 medications
• Whether weight returns after treatment stops
• The effects of long-term use on growth and development
• Potential nutritional deficiencies if children eat significantly less
• Whether medication could unintentionally replace healthy lifestyle habits

Common side effects include nausea, vomiting, diarrhea, and other gastrointestinal symptoms. Although uncommon, more serious complications can include pancreatitis and gallbladder disease.

Dr. Sarah Hampl, who works in the pediatric obesity program at Children’s Mercy Hospital in Kansas City, believes more research is needed before expanding treatment to younger children. She said:

We do not have enough evidence to safely prescribe under 12 at this point… I think that potential is there for positive impact, but there are not enough studies yet.

Drug manufacturers are also proceeding cautiously. Novo Nordisk, the maker of Wegovy, does not promote off-label prescribing, although it is studying the medication in children as young as six. Eli Lilly is conducting similar research with Zepbound.

Even among families who have seen success with GLP-1 medications, the goal is not lifelong dependence on the drugs. The parents of Ayden and Kayden hope the medication will provide a window of opportunity for their sons to establish sustainable habits that last well beyond treatment. As their father explained:

They can learn to manage themselves, the exercise, the healthy habits, read their bodies properly. The goal is for them to learn that, you know, as they grow, this is going to be their life.

This perspective reflects the broader approach recommended by obesity specialists, who generally view medication as one part of a comprehensive treatment plan that includes nutrition, physical activity, behavioral counseling, and family support.

Even for patients who qualify, obtaining GLP-1 medications can be difficult because of cost and insurance coverage. To improve access for eligible older adults, Medicare launched the temporary GLP-1 Bridge Program on July 1. The program allows qualifying Medicare Part D beneficiaries to receive eligible weight-loss medications, including Wegovy and certain formulations of Zepbound, for a $50 monthly copay while broader coverage policies continue to evolve.

Families with younger children, however, often face significant financial barriers. Off-label prescriptions are frequently not covered by insurance, leaving parents responsible for hundreds of dollars each month.

For now, experts remain divided. While some see early treatment as an opportunity to prevent serious disease, others believe the science has not yet caught up with the growing interest in prescribing these medications to children under 12.

Your responses and feedback are welcome!

Source: “Fact Check Team: How young is too young for GLP-1 medications?,” The National News Desk, 7/10/26
Source: “Kids as young as six are being given weight-loss drugs as a way to curb obesity before it gets too late,” The Independent, 06/22/26
Image by Tima Miroshnichenko/Pexels